Zentalis doses first Phase 3 patient, selects pivotal dose; cash drops $121M to $212M

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

Key Changes

• high

  Company dosed first patient in Phase 3 ASPENOVA trial (May 2026) and selected 400mg as pivotal monotherapy dose for DENALI Part 2 (April 2026), advancing azenosertib toward potential full approval in Cyclin E1-positive ovarian cancer.

  MD&A: Clinical Development verify on EDGAR →
• high

  Cash and marketable securities fell from $332.5M (March 2025) to $211.8M (March 2026), a $121M decline over 12 months, yet management maintains runway estimate of 'into late 2027' unchanged from prior year.

  MD&A: Liquidity verify on EDGAR →
• medium

  ASPENOVA trial initiation triggered $7M milestone payment owed to Recurium IP Holdings, a near-term cash obligation disclosed for the first time this quarter.

  MD&A: Recurium Agreement verify on EDGAR →